Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05978-4 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Annals of Hematology, 2024. Verfasst von Shenmiao Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China. Hauptthemen laut MEDLINE: Pyrazines, Leukemia, Lymphocytic, Chronic, B-Cell, Benzamides. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acalabrutinib is a highly selective Bruton tyrosine kinase inhibitor approved in the United States and Europe for chronic lymphocytic leukemia (CLL) based on phase 3 trials with limited representation of Asian populations. This phase 1/2 trial evaluates acalabrutinib in Chinese adults with relapsed/refractory (R/R) CLL receiving acalabrutinib 100 mg twice daily in 28-day cycles until disease progression or treatment discontinuation due to adverse events (AEs) presenting substantial clinical risk. The primary endpoint was blinded independent central review (BICR)-assessed overall response rate (ORR). A total of 60 patients from 20 sites in China received acalabrutinib (median age 62 years; median 1 prior therapy line; 21.7% with del(17p) and/or TP53 mutation; 51.7% with unmutated IGHV). Median total treatment duration was 19.4 months (range 0.6–28.2) with 53 patients (88.3%) receiving acalabrutinib at data cutoff; median study follow-up was 20.2 months. BICR-assessed ORR was 85.0% (95% CI, 73.4–92.9). Median duration of response, progression-free survival (PFS), and overall survival (OS) were not reached. Estimated 12-month and 18-month PFS rates were 91.5% (95% CI, 80.9–96.4) and 78.8% (95% CI, 60.9–89.2); OS rates were both 96.7% (95% CI, 87.3–99.2). AEs of grade ≥ 3 occurred in 25 patients (41.7%), most commonly decreased neutrophil count (13.3%, n = 8), pneumonia (6.7%, n = 4), and upper respiratory tract infection (6.7%, n = 4). AEs led to treatment discontinuation in 2 patients (paraneoplastic pemphigus; rectal neoplasm). This study demonstrated high ORR in acalabrutinib-treated Chinese patients with R/R CLL with no unexpected safety concerns. This trial is registered on ClinicalTrials.gov (NCT03932331).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China.
- The First Affiliated Hospital of Soochow University, Suzhou, China.
- Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
- Xiangya Hospital Central South University, Changsha, China.
- The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
- AstraZeneca, Shanghai, China.
Zitieren
APA
Yang, S., Huang, H., Zhou, K., Zhao, X., Han, Y., Li, L., Wang, Y., Liu, X., & Li, J. (2024). Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial. Annals of Hematology. https://doi.org/10.1007/s00277-024-05978-4
Vancouver
Yang S, Huang H, Zhou K, Zhao X, Han Y, Li L, et al. Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial. Annals of Hematology. 2024. doi:10.1007/s00277-024-05978-4
BibTeX
@article{Yang2024,
author = {Yang, Shenmiao and Huang, Haiwen and Zhou, Keshu and Zhao, Xielan and Han, Yanqiu and Li, Lindong and Wang, Yujie and Liu, Xiaofeng and Li, Jianyong},
title = {Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05978-4}
}
EUVIMED